Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation

Completed · Phase 4 · Has a placebo group

Conditions studied: Abortion

In brief

This is a research study to measure the effect of digoxin injection on Dilation and Evacuation (D\&E) procedure duration. Digoxin is the most commonly used feticidal agent among family planning subspecialists, and is commonly used for a variety of reasons including provider preference, patient preference, and concerns over legal status of later D\&E procedures. There have been several studies on digoxin administration, adverse effects, and impact on the D\&E procedure, but doctors want to clarify how digoxin effects D\&E procedure time, if at all.

Key facts

Study ID

NCT03136068

Run by

University of California, San Francisco

People needed

178

Starts

2017-02-23

Expected to finish

2018-05-31

Last updated by the study team

2019-10-30

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• 20 weeks 0 days-24 weeks 0 days gestation
• English or Spanish speaking
• 18 years or older

You may not qualify if…

• Under 18
• Contraindications to digoxin

Where it is running

• FPA Women's Health — Long Beach, California, United States
• SFGH Women's Options Center — San Francisco, California, United States
• Lovejoy Surgicenter — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.